Grace Therapeutics details GTx-104 resubmission plan after CRL, sets cash runway to 2028Aug 13Quarterly updateGrace Therapeutics Inc.
Ultragenyx reports Q2 2026 results, cites two PDUFA dates and Angelman readout aheadAug 4Quarterly updateapazunersenrebisufligene etisparvovec
Sign inSign in